Incyte Corp., of Wilmington, Del., reported that it recorded GAAP net product revenues of JAK inhibitor Jakafi (ruxolitinib) in the quarter ending Sept. 30 of $348 million, as compared to $304 million for the same period in 2017, representing 14 percent growth. For the nine-month period, net product revenues were $1 billion, as compared to $831 million for the same period last year, representing 21 percent growth. GAAP net product revenues of Iclusig (ponatinib) were $20 million in the third quarter, as compared to $18 million for the same period in 2017. For the nine-month period, net product revenues were $61 million, as compared to $47 million for the same period in 2017.